This program will continue to provide clinical and research training for physician and nonphysician postdoctoral fellows who wish to become qualified in treatment research for substance abusing patients, particularly drug abusing patients who are infected with or at high risk for becoming infected with the HIV virus; this includes patients who abuse drugs by the intravenous route as well as other at-risk groups such as those substance abusers who exchange sex for money or drugs. The predoctoral students will be trained in methodologies necessary for the development of programs on the treatment of substance abuse, as well as basic science techniques in genetics and neuroscience of substance abuse. In the process, all trainees will be fully educated in all the current behavioral, psychological and pharmacological techniques used in the treatment of patients who abuse or are dependent on various drugs of abuse. In addition, the trainees will be prepared to evaluate new treatments that may be proposed in the future and to conduct their own research on developing new treatments for existing and future alcohol and drug problems. The postdoctoral trainees will consist of about 60 percent board eligible psychiatrists, or physicians with backgrounds in neurology, internal medicine, pediatrics and other primary care specialties. In addition, about 40 percent of the fellows will be post-doctoral students in psychology, pharmacology, neuroscience, immunology and related fields. Two predoctoral students yearly will be in pharmacology or related disciplines.
Specific aims of this proposal include: 1. development of trainees for leadership roles in the field of substance abuse; 2. development of excellent clinical researchers in the field of substance abuse or basic researchers with a special appreciation of clinical problems in this area; 3. the inculcation of the basic tenets of clinical research design and the development of independent research projects; 4. the development of physicians and pre- and post-doctoral scientists who are able to critically evaluate the substance abuse clinical research literature and make independent contributions to the literature; and 5. the development of physicians and pre- and post-doctoral scholars/scientists who will be able to assume academic positions in medical school and graduate departments to enhance education/training and research in substance abuse at those institutions. The primary facilities are the University of Pennsylvania Addiction Research Center and our clinical affiliates, including the VA Medical Center Substance Abuse Treatment Program.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
5T32DA007241-15
Application #
7095173
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Grossman, Debra
Project Start
1990-07-01
Project End
2010-06-30
Budget Start
2006-07-01
Budget End
2010-06-30
Support Year
15
Fiscal Year
2006
Total Cost
$535,458
Indirect Cost
Name
University of Pennsylvania
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Mague, Stephen D; Port, Russell G; McMullen, Michael E et al. (2015) Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. Neuropharmacology 97:426-35
Goldman, Marina; Ehrman, Ronald N; Suh, Jesse J et al. (2015) Brief report: ""spiders-No, puppies-Go"", introducing a novel Go NoGo task tested in inner city adolescents at risk for poor impulse control. J Adolesc 38:45-8
Smith, Rachel J; Aston-Jones, Gary (2014) Incentive learning for morphine-associated stimuli during protracted abstinence increases conditioned drug preference. Neuropsychopharmacology 39:373-9
Goldman, Marina; Szucs-Reed, Regina P; Jagannathan, Kanchana et al. (2013) Reward-related brain response and craving correlates of marijuana cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects. J Addict Med 7:8-16
Goldman, Marina; Suh, Jesse J; Lynch, Kevin G et al. (2010) Identifying risk factors for marijuana use among veterans affairs patients. J Addict Med 4:47-51
Plebani, Jennifer G; Tirado, Carlos F; Pettinati, Helen M et al. (2010) Combined effects of alcohol and hepatitis C: a secondary analysis of alcohol use biomarkers and high-risk behaviors from two medication trials for alcohol dependence. Addict Behav 35:123-8
Mague, Stephen D; Blendy, Julie A (2010) OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108:172-82
Plebani, Jennifer G; Kampman, Kyle M; Lynch, Kevin G (2009) Early abstinence in cocaine pharmacotherapy trials predicts successful treatment outcomes. J Subst Abuse Treat 37:313-7
Mague, Stephen D; Isiegas, Carolina; Huang, Peng et al. (2009) Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A 106:10847-52
Suh, Jesse J; Langleben, Daniel D; Ehrman, Ronald N et al. (2009) Low prefrontal perfusion linked to depression symptoms in methadone-maintained opiate-dependent patients. Drug Alcohol Depend 99:11-7

Showing the most recent 10 out of 29 publications